A Study to Test the Safety/ Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects >=16 Years of Age With Partial Seizures With or Without Secondary Generalization

Inclusion Criteria: * Male/female study participant from 16 years of age or older. Study participant who are not legal adults may only be included where legally permitted and ethically accepted * Study participant completed the Treatment Period and Transition Period of EP0083 or is ongoing in N01379 sites in Japan * Female study participants with childbearing potential are eligible if they use a medically accepted contraceptive method * Inclusion Criteria for directly enrollers only: Study participant has 1 to \<8 partial seizures (according to the 1981 International League Against Epilepsy (ILAE) classification) during the 8 weeks prior to brivaracetam (BRV) administration Exclusion Criteria: * Study participant has developed hypersensitivity to any components of the investigational medicinal product (IMP) or comparative drugs as stated in this protocol during the course of the core study * Severe medical, neurological or psychiatric disorders, or laboratory values which may have an impact on the safety of the study participant * Poor compliance with the visit schedule or medication intake in the previous BRV studies * Planned participation in any other clinical study of another investigational drug or device during this study * Pregnant or lactating woman * Any medical condition which, in the Investigator's opinion, warrants exclusion * Study participant has a lifetime history of suicide attempt or has suicidal ideation in the past 6 months * Study participant has \>2 x …